Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Michael J. Overman(The University of Texas MD Anderson Cancer Center), Thierry André(Inserm), Scott Kopetz(The University of Texas MD Anderson Cancer Center), Rebecca A. Moss(Bristol-Myers Squibb (United States)), Michael D. Axelson(Bristol-Myers Squibb (United States)), Gregory A. Maglinte(Bristol-Myers Squibb (United States)), Jean-Marie Ledeine(Bristol-Myers Squibb (Belgium)), Heinz‐Josef Lenz(USC Norris Comprehensive Cancer Center), Sara Lonardi(Istituto Oncologico Veneto), Andrew Hill(University of Auckland), Joseph L. Leach(Allina Health), Michael A. Morse(Duke Medical Center), Jayesh Desai(Peter MacCallum Cancer Centre), Z. Alexander Cao(Bristol-Myers Squibb (United States)), Monica V. Goldberg(Bristol-Myers Squibb (United States)), Ray McDermott(St. Vincent's University Hospital)
Cited by 2,813
Related Papers
Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
|New England Journal of Medicine|2020|2.9k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k
Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer
|Science Translational Medicine|2016|1.5k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k